ACET
- Adicet Bio, Inc.
()
Overview
Company Summary
Adicet Bio, Inc. is a biotechnology company that focuses on the development of immunotherapies for cancer treatment. The company utilizes its proprietary technology platform known as "Targeted Immunomodulation." This platform allows Adicet Bio to engineer immune cells called natural killer (NK) cells and T cells, which are then used to target and destroy cancer cells.
Adicet Bio's approach involves modifying these immune cells to express chimeric antigen receptors (CARs) or T cell receptors (TCRs) that specifically recognize and bind to tumor-specific antigens. This enables the engineered immune cells to directly attack cancer cells, initiating an immune response to eradicate the tumors.
The company's pipeline includes various CAR-NK cell and CAR-T cell therapies, which are being developed for the treatment of different types of cancers. Adicet Bio aims to leverage the unique properties of NK cells, such as their ability to be used off-the-shelf and their potential to target multiple tumor types, to develop effective and safe cancer therapies.
Through its research and development efforts, Adicet Bio seeks to advance the field of immunotherapy by expanding the efficacy and applicability of cellular therapies for cancer treatment. The company collaborates with academic institutions, biopharmaceutical companies, and other organizations to further its mission of developing transformative immunotherapies to improve patient outcomes.
Overall, Adicet Bio, Inc. is dedicated to harnessing the power of the immune system to revolutionize cancer treatment and provide novel therapeutic options for patients battling this disease.